NLBNPIT1ZPQ2 20241220 180 (P1ZPQ2) News

Allurion Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight Loss

Patients gained an average of 5.6% in lean body mass during the Allurion Program Separate studies of patients on GLP-1 therapy report an average...

Allurion Announces Three Scientific Presentations at the 40th Annual Meeting of the American Society for Metabolic and Bariatric Surgery

New data show 22.1% weight loss at one year with consecutive Allurion Balloons, approaching weight loss surgery outcomes Allurion Technologies...

Form 4 - Statement of changes in beneficial ownership of securities

Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer

Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief...

Allurion Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s

Company also announces first commercial agreements for the Virtual Care Suite in the United States Allurion Technologies, Inc. (NYSE: ALUR), a...

Allurion to Participate in Two Upcoming Investor Conferences in June 2024

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in two upcoming...

Allurion Announces Three Scientific Presentations at the European Congress on Obesity, Including Study on Lean Mass Preservation for Sustainable, Healthy Weight Loss

New data demonstrate significant fat mass loss while preserving lean mass Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Allurion Reports First Quarter 2024 Financial Results and Provides Business Update

Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Allurion Announces Three Scientific Presentations at IFSO-European Chapter 2024, Including First-Ever 3-Year Weight Maintenance Survey

New data demonstrates 80% sustained weight loss at three years with the Allurion Program and initial positive outcomes of a novel, generative...

Allurion Announces Preliminary First Quarter 2024 Results

Generated quarter-over-quarter revenue growth and continued growth in procedural volume, while substantially reducing cash burn Company to report...

Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments

Simplifies capital structure through prepayment of existing term loan Reduces annual interest expense, providing increased near-term cash flow...